Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Condition:   Neoplasms
Interventions:   Drug: VIP152 (BAY 1251152);   Drug: VIP152 (BAY 1251152) 30 mg;   Drug: Keytruda;   Drug: VIP152 (BAY 1251152) 15 mg
Sponsor:   Vincerx Pharma, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 1, 2022Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments